Mary Bates is a freelance science writer based in Boston, Massachusetts. Her work has been published by National Geographic News, New Scientist, BrainFacts.org, and other print and online publications.
As cancer rates rise among younger adults, researchers look for new screening and treatment options.
Recently, the opioid epidemic is dominating news headlines and inspiring greater calls for political action in the United States. While opioid addiction isn’t a new issue, its devastating consequences are now being felt across the country. New and emerging treatments for opioid addiction hope to offer solutions to this crisis.
Researchers are discovering a link between depression and gut bacteria.
Paralysis, whether caused by spinal cord injury, neurodegenerative disease, or other factors, poses a host of issues for patients. These include not just the inability to move parts of their bodies but potential problems with communication and bladder control as well. Fortunately, the last decade has seen promising technology advances to address these concerns.
Most people don’t worry about small cuts or wounds, because their bodies form clots to stop the bleeding. This process, called coagulation or hemostasis, requires certain blood cells, platelets, and protein clotting factors to interact correctly and form a clot to stanch the bleeding and begin repair of the damaged blood vessel.
Advances in automated data processing and machine learning now allow epidemiologists to meticulously sift through the millions of digital traces we collectively leave behind each day as we conduct our lives online—through Internet searches, social media posts, or the use of our mobile phones.
At first, palliative care and technology might seem like strange bedfellows. At its core, palliative care is a very human side of medicine, relying heavily on talking with and listening to people to understand their experiences and goals. Technology, on the other hand, can often
As a growing epidemic of opioid abuse in the United States can attest, pain, and how to treat it effectively and without serious side effects, is one of the foremost challenges in medicine today.
IEEE Pulse recently spoke with Craig Lipset, head of Clinical Innovation at Pfizer, about new trends and approaches in clinical trials.
We are in the midst of a CRISPR craze. The last five years have seen the publication of over 1,000 scientific papers, the allocation of millions of research dollars, and the establishment of four start-up companies in the United States alone.